← All trials
NCT06233110
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2024
- Primary completion
- Jan 1, 2029
- Completion date
- Jul 1, 2029
- First posted
- Jan 31, 2024
- Last posted
- Sep 27, 2024
- Enrollment
- 30
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Duke UniversityOfficial
- National Institutes of Health (NIH)Collaborator
- Rigel PharmaceuticalsCollaborator
- Duke UniversitySponsor investigator
- IncyteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.